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Family history is an independent risk factor for diabetes, but it is not clear how much adding family history to other
known risk factors would improve detection of undiagnosed diabetes in a population. Using the National Health and
Nutrition Examination Survey for 1999 2004, the authors compared logistic regression models with established
risk factors (model 1) with a model (model 2) that also included familial risk of diabetes (average, moderate, and
high). Adjusted odds ratios for undiagnosed diabetes, using average familial risk as referent, were 1.7 (95%
conﬁdence interval (CI): 1.2, 2.5) and 3.8 (95% CI: 2.2, 6.3) for those with moderate and high familial risk, re-
spectively. Model 2 was superior to model 1 in detecting undiagnosed diabetes, as reﬂected by several signiﬁcant
improvements, including weighted C statistics of 0.826 versus 0.842 (bootstrap P ¼ 0.001) and integrated dis-
crimination improvement of 0.012 (95%CI: 0.004, 0.030). With a risk threshold of 7.3% (sensitivity of 40% based on
model 1), adding family history would identify an additional 620,000 (95% CI: 221,100, 1,020,000) cases without
a signiﬁcant change in false-positive fraction. Study ﬁndings suggest that adding family history of diabetes can
provide signiﬁcant improvements in detecting undiagnosed diabetes in the US population. Further research is
needed to validate the authors’ ﬁndings.
decision analysis; logistic regression; mass screening; model ﬁtting; nutrition surveys; risk
Abbreviations: AIC, Akaike Information Criterion; CDC, Centers for Disease Control and Prevention; CI, conﬁdence interval;
NHANES, National Health and Nutrition Examination Survey; ROC, receiver-operating characteristic.
Family history is a consistent risk factor for many chronic
diseases of public health signiﬁcance (1) and, in the past few
years, it has increasingly been discussed as a tool for pre-
venting common diseases and for promoting health (2–4). In
2005, the US Surgeon General launched a public health
campaign to enhance the public’s awareness of the impor-
tance of family history (http://www.hhs.gov/familyhistory/),
and the Centers for Disease Control and Prevention (CDC)
has initiated a public health research initiative on this topic.
The CDC’s initiative is focused primarily on several com-
mon chronic diseases, including diabetes, stroke, heart dis-
ease, and cancers (http://www.cdc.gov/genomics/famhistory
/index.htm). Yet, in spite of the increased interest in family
history as a public health tool, the clinical validity and utility
of this readily obtained risk factor have not been systemat-
ically evaluated.
In the present study, we assessed the improvements in
detecting undiagnosed diabetes among US adults that might
be obtained by using information on family history. Among
an estimated 24 million individuals with diabetes in the
United States in 2007 (based on fasting plasma glucose),
28% (6.6 million) were undiagnosed (5). One of the ratio-
nales for asking undiagnosed people about their family his-
tory is that a number of diabetes risk models/tools have
included family history of diabetes as a risk factor, with
an estimated relative risk 2–6 times that of people without
family history (6–15). Furthermore, other studies suggest
that family history might be an effective screening tool for
identifying both diabetes and undiagnosed diabetes (1, 3,
14, 16–18). Even so, none of these studies has formally
evaluated the improvements in detecting undiagnosed dia-
betes by using family history. This is important in part
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gested that a signiﬁcant and independent risk factor for
a disease does not necessarily increase the ability of detect-
ing the disease or to enhance the discrimination ability be-
tween people with and without disease (19).
Receiver-operating characteristic (ROC) curves and the
associated C statistics are commonly used to summarize
the diagnostic accuracy of risk models and to assess the
improvements made to such models that are gained from
adding other risk factors (20). Some studies, however, have
criticized ROC curves for lacking the ability to display the
risk in a particular population and to assess the reclassiﬁ-
cation of individuals into different risk groups (e.g., higher
risk, lower risk) (19, 21). Recently, researchers have de-
veloped several alternative methods to assess the improve-
m e n t sm a d eb yan e wm a r k e ro rr i s kf a c t o ri nr i s km o d e l s
(22–25). Predictiveness curves, for example, display the
distribution of risk in the population and also assess the
classiﬁcation ability of additional risk factors (24). Alter-
natively, the net reclassiﬁcation improvement and inte-
grated discrimination improvement integrate sensitivity,
speciﬁcity, and the information from reclassiﬁcation tables
to assess improvements in risk models that include new
risk factors (23). A third method involves net beneﬁt
curves, which might help to determine whether it would
be cost-effective to include an additional risk factor in the
risk model (25). We applied both conventional and recently
developed methods to assess the improvements made from
using family history to detect cases of undiagnosed diabe-
tes among adults. Our source of data was the National
Health and Nutrition Examination Survey (NHANES) for
1999–2004.
MATERIALS AND METHODS
NHANES is a series of stratiﬁed, multistage probability
surveys designed to obtain information on the health and
nutritional status of the civilian, noninstitutionalized US
population. From 1999, NHANES data have been collected
continuously, with every 2 years serving as 1 analytical
cycle. The data are collected by the National Center for
Health Statistics, CDC, via household interviews and phys-
ical examinations and are intended to provide estimates
that are representative of the US population. Detailed in-
formation is available elsewhere (http://www.cdc.gov/nchs/
nhanes.htm). The present study included 3 cycles (1999–
2000, 2001–2002, and 2003–2004) of samples of adults
aged  20 years who were examined in the morning after
overnight fasting (between 8 and 23 hours) and did not have
diagnosed diabetes. When analyzing combined data sets, we
found that the sampling weights must be recalculated to
produce unbiased estimates, because weights for the
1999–2000 cycle were based on population data prior to
the 2000 US Census, and weights for the other cycles were
based on the 2000 US Census. Detailed NHANES analytic
and reporting guidelines that provide algorithms to recalcu-
late the sampling weights can be found at the following
website: (http://www.cdc.gov/NCHS/data/nhanes/nhanes_
03_04/nhanes_analytic_guidelines_dec_2005.pdf).
Undiagnosed diabetes and family history of diabetes
We excluded pregnant women and persons with diag-
nosed diabetes, with unknown diabetes status, and with
missing values for some of the covariates. Participants with
a fasting plasma glucose level of  126 mg/dL (7.0 mmol/L)
who reported no previous diagnosis of diabetes were deﬁned
as cases of undiagnosed diabetes (26).
We classiﬁed all participants into 3 mutually exclusive
groups of familial risk on the basis of their family history
of diabetes among ﬁrst- and second-degree relatives: 1) high
(at least 2ﬁrst-degree relativesor 1 ﬁrst-degree and at least 2
second-degree relativesfrom the same lineage); 2) moderate
(just 1 ﬁrst-degree and 1 second-degree relative with diabe-
tes, or only 1 ﬁrst-degree relative with diabetes, or at least 2
second-degree relatives with diabetes from the same mater-
nal or paternal line); or 3) average (no family history of
diabetes or, at most, 1 second-degree relative with diabetes)
(15). We use the term ‘‘family history of diabetes’’ to mean
all 3 groups (high, moderate, and average). Limited
information on family history of diabetes in NHANES
1999–2004 does not allow further detailed analysis.
Risk models
We used logistic regression models to calculate the pre-
dicted risk for undiagnosed diabetes. To select the appropri-
ate models, we started with the list of those risk factors
suggested by the American Diabetes Association that were
available in NHANES 1999–2004 (27); these risk factors
included age, race/ethnicity (non-Hispanic white, non-
Hispanic black, Mexican American, others), body mass in-
dex, physical activity (inactive, irregularly active, regularly
active), hypertension ( 140/90 mm Hg or on therapy for
hypertension), a high density lipoprotein cholesterol level
of  35 mg/dL (0.90 mmol/L) and/or a triglyceride level
of  250 mg/dL (2.82 mmol/L), history of cardiovascular
disease, and family history of diabetes. We used the back-
wards selection approach, including all suggested risk fac-
tors in the multiple logistic regression models with a ¼ 0.10
to select the ﬁnal models (28, 29). These ﬁnal models in-
cluded age, gender, body mass index, hypertension, low
high-density lipoprotein cholesterol and/or elevated triglyc-
erides, and family history of diabetes. We found no evidence
of multicollinearity among the selected risk factors (30). We
tested interactions between family history and other risk
factors by including the product terms in the risk models
based on the Satterthwaite-adjusted F test. There is no ev-
idence of signiﬁcant interaction. We also included age as
a nonlinear term, the logarithm of high density lipoprotein
cholesterol as a continuous variable, and the interaction
between body mass index and high density lipoprotein cho-
lesterol in the model. The full model does not offer signif-
icant improvements over the main effect models (results not
shown). For simplicity, we used the main effects models.
Similar sets of risk factors have been used and validated by
other studies using the NHANES data (15, 31, 32). For
assessments of the improvements in detecting undiagnosed
diabetes by using family history of diabetes, we calculated 2
risk models: one that had the selected risk factors excluding
family history of diabetes (model 1) and the other with the
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2, nested model).
Statistical analysis
The adjusted and weighted prevalence and odds ratios and
95% conﬁdence intervals for undiagnosed diabetes were
obtained by logistic regression models by using the pre-
dicted margins by the 3 categories of family history of di-
abetes (33).The prevalence and odds ratios were adjusted by
the risk factors selected for the ﬁnal model. We estimated
the mean and standard error for continuous variables, pro-
portions for categorical variables, and their 95% conﬁdence
intervals by levels of family history of diabetes. We tested
for signiﬁcant differences in the mean and prevalence across
levels of family history of diabetes based on Satterthwaite-
adjusted F statistics and on the v
2 test, respectively. All tests
were 2 tailed at the a ¼ 0.05 level of signiﬁcance.
Assessment of risk models and improvements from
using family history in detection of undiagnosed
diabetes
For the global measure of models’ ﬁt, we used the Akaike
Information Criterion (AIC) estimated from the logistic re-
gression models; a difference in AIC between 2 models
of >2 was interpreted as a signiﬁcant improvement for the
model with the smaller AIC (34). For models’ calibration,
we calculated Hosmer-Lemeshow goodness-of-ﬁt statistics
on the basis of deciles of risk (29). For the discrimination
abilities of family history of diabetes, we constructed the
weighted ROC curvesand calculated the C statistics (35).To
test for the signiﬁcance of differences between AIC values,
between weighted ROC curves, and between C statistics of
different risk models, we used the rescaling bootstrap
method of Cheng et al. (36) and Rao et al. (37) that takes
into account the complex survey design by changing the
sampling weights for each resample. We generated 1,000
rescaled bootstrap weights, calculated the distribution for
the 2.5 and 97.5 percentiles, and reported these values as
the 95% conﬁdence intervals of the differences between
different risk models (38).
The predictiveness curve described earlier is an integrated
plot of predicted risks from logistic regression models
formed by the percentiles of risk in the population (24).
From the predictiveness curves, one could read off the
predicted probability of an event for any corresponding
true-positive fraction (sensitivity) or false-positive fraction
(1   speciﬁcity). We constructed the weighted predictive-
ness curves. For the summary measure of weighted predic-
tiveness curves, we calculated the proportion-explained
variations (R
2) for each risk model and used the rescaling
bootstrap method to make the inference about signiﬁcant
differences between the different R
2 variations (37). The
difference between R
2 variations is equivalent to the inte-
grated discrimination improvement index proposed by
Pencina et al. (23) and Pepe et al. (39) that measures the
ability of the additional risk factor to increase the predicted
probability among those who had the event and to decrease
the predicted probability among those who were event
free (23).
For risk prediction, it is important to examine if the model
with the additional risk factor can more accurately stratify
individuals into higher or lower risk categories (risk reclas-
siﬁcation) (21). Some recently developed risk reclassiﬁca-
tion measures require use of recognized risk thresholds
(22, 23), but at present no researchers or clinicians have
proposed any risk classiﬁcation schemes (risk thresholds)
for clinical use in identifying higher- or lower-risk patients
for diabetes. Nor have they proposed follow-up tests such
as glucose testing for people at higher or lower risk to
identify those who really have diabetes. Accordingly, we
used logistic regression model 1 to determine the predicted
probability of events that corresponded approximately to
20%, 40%, 60%, and 80% of undiagnosed diabetes (di-
chotomous cutpoints at quintiles of sensitivity) and used
these probability thresholds to identify the true-positive
fraction and false-positive fraction from the predictiveness
curves. We also calculated the net reclassiﬁcation improve-
ment index, positive predictive values, and negative pre-
dictive values for each dichotomous risk threshold for
model 1 and model 2, respectively. The net reclassiﬁcation
improvement index is a special case of integrated discrim-
ination improvement with the recognized risk thresholds
(23). We used the rescaled bootstrap method with 1,000
samples to estimate the 95% conﬁdence intervals of inte-
grated discrimination improvement and net reclassiﬁcation
improvement (39).
To help to determine whether including a risk factor in
a risk model might be cost-effective, we used decision curve
analysis (25). Brieﬂy, decision curve analysis estimates the
net beneﬁt of a model by taking the difference between the
number of true positives and the number of false positives
weighted by the odds of the selected threshold probability of
risk for a range of threshold probabilities (25, 40). The net
beneﬁtof a modelcompared with the reference net beneﬁtor
compared with another modelmight be interpreted as the net
increase in the proportion of cases identiﬁed. The reference
was calculated by assuming that all people were tested for
the events, and testing no onewas set to a net beneﬁt of zero.
For any given threshold probability cutpoint, the risk models
with the higher net beneﬁt are the preferred model (41). We
calculated and plotted theweighted net beneﬁtcurves for the
reference model (testing all), model 1, and model 2, respec-
tively. We used the quintile cutpoints of the predicted prob-
abilities to compare the net beneﬁts curves of model 1 and
model 2 and calculated the differences in the net beneﬁt
between the 2 models for the each cutpoint and 95% conﬁ-
dence interval of difference between the 2 models using the
rescaled bootstrap method. Unless otherwise speciﬁed, data
were analyzed by using SAS, version 9.2, software (SAS
Institute, Inc., Cary, North Carolina) and SUDAAN, release
9.0, software (Research Triangle Institute, Research Trian-
gle Park, North Carolina) to account for the complex sam-
pling design of NHANES 1999–2004 (42).
RESULTS
NHANES 1999–2004 surveyed 5,551 adults aged  20
yearswithoutdiagnoseddiabeteswhowereaskedforablood
sample after fasting overnight. The 498 persons excluded
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abetes status, and 173 peoplewith missing covariates. Of the
ﬁnal sample (n ¼ 5,053), 73.6% were non-Hispanic white;
10.5%, non-Hispanic black; 7.2%, Mexican American; and
8.8%, other race/ethnicity.
The prevalence of undiagnosed diabetes, adjusted odds
ratios, and characteristics of the people by level of familial
risk of diabetes are summarized in Table 1. The prevalence
increased signiﬁcantly with level of familial risk from 2.2%
(95% conﬁdence interval (CI): 1.7, 2.6) to 7.2% (95% CI:
4.2, 10.1) (P ¼ 0.001). The adjusted odds ratio increased
from 1.7 (95% CI: 1.2, 2.5) to 3.8 (95% CI: 2.2, 6.3) for
moderate and high familial risk, respectively. Familial risk
of diabetes was signiﬁcantly associated with all the selected
covariates except for physical activity.
Assessing improvements in the detection of
undiagnosed diabetes by using family history
Table 2 includes several statistical measures of overall ﬁt,
discrimination ability, and reclassiﬁcation of risk for models
1 and 2. Compared with model 1, model 2 represented
signiﬁcant improvements in 3 statistical measures in detect-
ing undiagnosed diabetes: a lower AIC, a signiﬁcant
Table 1. Characteristics of Participants by Family History of Diabetes, National Health and Nutrition Examination Survey, 1999–2004
Characteristic Sample,
no.
Familial Risk of Diabetes
P Value
a
Average
(n 5 3,526) 95% CI Moderate
(n 5 1,150) 95% CI High
(n 5 377) 95% CI
Prevalence of undiagnosed
diabetes, %
200 2.2 1.7, 2.6 3.6 2.5, 4.7 7.2 4.2, 10.1 0.001
Adjusted odds ratio
b 1.0 1.7 1.2, 2.5 3.8 2.2, 6.3 <0.001
Mean age, years (SE) 5,053 44.7 (0.43) 46.5 (0.75) 47.3 (0.87) 0.002
Gender, %
Male 2,556 49.9 48.5, 51.4 48.5 45.3, 51.8 41.6 35.0, 48.5
Female 2,497 50.1 48.6, 51.5 51.5 48.2, 54.7 58.4 51.5, 65.0 0.046
Race/ethnicity, %
Non-Hispanic white 2,682 74.8 71.2, 78.1 72.6 67.6, 77.0 63.5 55.3, 70.9
Non-Hispanic black 907 9.8 7.9, 12.0 11.1 8.6, 14.2 16.3 11.9, 21.8
Mexican American 1,131 6.6 5.2, 8.3 8.4 5.9, 11.7 10.3 7.3, 14.4
Other (including other Hispanic) 333 8.9 6.6, 11.9 8.0 5.4, 11.5 9.9 6.0, 15.9 <0.001
Body mass index category, %
<18.5 kg/m
2 71 2.1 1.6, 2.9 1.0 0.5, 2.1 1.0 0.3, 3.2
18.5–24.9 kg/m
2 1,628 37.4 35.1, 39.8 27.7 24.2, 31.5 26.9 21.2, 33.6
25–29.9 kg/m
2 1,843 34.7 32.3, 37.2 35.9 32.4, 39.5 35.1 27.7, 43.2
 30 kg/m
2 1,511 25.8 23.7, 27.9 35.4 32.4, 38.5 37.0 30.5, 44.0 <0.001
Physical activity (n ¼ 4,889), %
Inactive 2,023 33.4 31.0, 35.8 36.2 32.8, 39.7 39.5 33.7, 45.7
Irregularly active 1,649 38.5 36.5, 40.6 36.3 32.0, 40.9 36.8 30.5, 43.5
Regularly active 1,240 28.1 25.8, 30.5 27.5 23.6, 31.8 23.7 18.6, 29.7 0.136
Hypertension, %
Yes 2,010 31.2 29.2, 33.4 38.0 34.8, 41.3 40.0 33.9, 46.3
No 3,043 68.8 66.6, 70.8 62.0 58.7, 65.2 60.0 53.7, 66.1 <0.001
Lipid, %
HDL-C of  35 mg/dL or
triglycerides of  250 mg/dL
851 15.4 14.0, 16.9 20.8 17.6, 24.5 21.2 15.7, 27.9
Other 4,202 84.6 83.1, 86.0 79.2 75.5, 82.4 78.8 72.1, 84.3 0.011
History of heart disease, %
Yes 371 4.9 4.1, 5.7 5.9 4.4, 7.9 10.5 7.2, 15.0
No 4,654 95.1 94.3, 95.9 94.1 92.1, 95.6 89.5 85.0, 92.8 0.005
Overall 5,053 71.9 69.9, 73.7 21.8 20.0, 23.8 6.3 5.5, 7.2 <0.001
Abbreviations: CI, conﬁdence interval; HDL-C, high density lipoprotein cholesterol; SE, standard error.
a For prevalence and odds ratios of undiagnosed diabetes, P values were for the trend across the categories of family history of diabetes based
on the Satterthwaite-adjusted F test; for categorical variables, P values were based on the v
2 test; all tests were 2 tailed.
b Adjustedfor age, gender, bodymass index, hypertension, a HDL-C level of  35 mg/dL (0.90mmol/L) and/or a triglyceride level of  250 mg/dL,
and family history of diabetes.
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improvement in reclassiﬁcation as measured by integrated
discrimination improvement. Models 1 and 2 demonstrated
similar levels of calibration (goodness-of-ﬁt tests), suggest-
ing the adequate ﬁt of both models.
Figure 1A plots the weighted predictiveness curves, and
Figure 1B shows the weighted true-positive fraction and
false-positive fraction by risk percentiles in the population.
These graphs show that using family history of diabetes, in
addition to the selected risk factors, reclassiﬁed the people
withundiagnoseddiabetestothehigherpredictedriskandthe
diabetes-free people to the lower predicted risk. Appendix
Table1presentsadetailedanalysisoftheselectedriskthresh-
olds. In a comparison of model 2 with model 1, for a higher
risk threshold (e.g., at 7.3%, or approximately the 89th per-
centile of risk distribution in the population) (Figure 1), the
weighted true-positive fraction (Appendix Table 1) increased
from 40.0% (95% CI: 29.4, 51.5) in model 1 to 49.4% (95%
CI: 37.9, 60.9) in model 2. The weighted positive predictive
valuerosefrom11.0%(95%CI:8.5,14.4)to14.2%(95%CI:
10.9,18.2),andthenetreclassiﬁcationimprovementinmodel
2 was 10.1% (95% CI: 1.0, 18.1; P ¼ 0.009). The weighted
false-positive fraction and the negative predictive value re-
mained largely unchanged at this risk threshold. At this level
of risk, model 2 would identify approximately 620,000 (95%
CI: 221,100, 1,020,000) more cases of undiagnosed diabetes
in the population than would model 1 (2.64 million vs. 3.26
million). As the risk thresholds lowered, model 2 was asso-
ciated with a decreased false-positive fraction and little
change in negative predictive value compared with model
1. However, these changes were not signiﬁcant enough to
have a signiﬁcant improvement in risk reclassiﬁcation indi-
cated by net reclassiﬁcation improvement.
Decision curves analysis
Figure 2 presents the weighted net beneﬁt curves derived
for testing all people versus testing strategies based on
model 1 and model 2. Model 2 appeared to offer greater
net beneﬁt across most risk thresholds, especially from the
predicted risk of around 5% to 15%. Both of the model-
based net beneﬁts were higher than testing all (the reference
testing strategy). Appendix Table 2 presents the detailed
analysis of net beneﬁts for 4 selected risk thresholds. Com-
paring model 2 with model 1, for example, at a 7.3% risk
threshold (40% sensitivity based on model 1), the difference
of net beneﬁt equals 0.32 per 100 people (95% CI: 0.06,
0.58), indicating that 3 extra cases of undiagnosed diabetes
would be detected per 1,000 subjects based on model 2. The
differences in net beneﬁts between the 2 models diminished
at either higher or lower risk thresholds, especially at the
lower risk thresholds.
DISCUSSION
This study conﬁrms that family history of diabetes is an
independent risk factor for undiagnosed diabetes, a ﬁnding
that is consistent with those of many other studies (6–15,
43). Recent National Institutes of Health state-of-the-
science statements on family history recognized the impor-
tant role of family history in the practice of medicine,
motivation of positive lifestyle changes, and inﬂuence of
clinical interventions (44). Our study assessed the improve-
ments in detecting undiagnosed diabetes that would come
from including family history in risk assessment and pop-
ulation screening. Our ﬁndings suggest that using a risk
model with family history of diabetes offers signiﬁcant im-
provements over a model with common risk factors in de-
tecting undiagnosed diabetes, especially among populations
at higher risk. For example, by using a risk threshold of
7.3% (the median predicted risk ¼ 1.3% in the population),
approximately 11% of the population had a predicted
risk  7.3% based on model 1. With model 2 we had a net
reclassiﬁcation improvement of 10.1% (95% CI: 1.0, 18.1;
P ¼ 0.009) that was mainly due to the increase in
Table 2. Comparison of 2 Models’Fit, Discrimination Ability, and Risk Reclassiﬁcation, National
Health and Nutrition Examination Survey, 1999–2004
Statistical Measures of
Undiagnosed Diabetes
Models Difference
(Model 1 2
Model 2)
95% CI
a
Without Family
History (Model 1)
b
With Family
History (Model 2)
c
AIC
d 590 579 10.9 1.4, 24.3
Goodness-of-ﬁt test
e 12.6 (0.126) 7.0 (0.534)
Weighted C statistics 0.826 0.842 0.016 0.005, 0.031
R
2/IDI 0.055 0.067 0.012
f 0.004, 0.030
Abbreviations: AIC, Akaike Information Criterion; CI, conﬁdence interval; IDI, integrated dis-
crimination improvement.
a The 2.5 and 97.5 percentile distributions of 1,000 rescaled bootstrap samples of the differ-
ences between the different risk models.
b Model 1 was adjusted for age, gender, body mass index, hypertension, and a high density
lipoprotein cholesterol level of  35 mg/dL (0.90 mmol/L) and/or a triglyceride level of  250 mg/dL.
c Model 2 included, in addition to the risk factors in model 1, family history of diabetes.
d The means and differences of AIC were generated from 1,000 rescaled bootstrap samples for
the different risk models.
e Hosmer-Lemeshow goodness-of-ﬁt test; the numbers are v
2, with P values in parentheses.
f The difference between the R
2 of the 2 risk models equals the IDI.
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model 1 to 49.4% (95% CI: 37.9, 60.9) in model 2, a 24%
increase in the number of undiagnosed diabetes cases
identiﬁed. In other words, using model 2 at a risk threshold
of 7.3%, one would identify approximately 3.26 million
cases instead of 2.64 million cases of undiagnosed diabetes
of an estimated 6.6 million total cases without an increase in
false-positive fraction.
Some researchers have argued that the statistical mea-
sures of risk models for performance in prediction and re-
classiﬁcation have limited value for evaluation of the
clinical utility of the additional risk factor/marker because
they do not consider cost-effectiveness (25, 41, 45). How-
ever, the traditional cost-effectiveness analysis of diagnostic
tests has involved collecting additional data on alternative
treatments that couldinvolve substantial cost and sometimes
might be difﬁcult to collect (46, 47). The decision curve
analysis, which does not require collecting additional data
on cost and effectiveness, offers a simple approach to ex-
amining the clinical consequences of alternative testing
strategies and to comparing the different risk models in
terms of net beneﬁts over a range of predicted probabilities
for an event (25). The focus of the net beneﬁt curves is not
on any particular point estimate, but rather on the entire
range of threshold probabilities in a way that one net beneﬁt
curve is greater or lesser than the other alternatives (25, 48).
Our ﬁndings indicate that the net beneﬁt curves derived
from model 2 (versus model 1) were greater over nearly
the whole range of risk thresholds, especially from 5% to
15% predicted risks, indicating the net beneﬁt of detecting
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Figure 1. Weighted predictiveness curves (A) and true-positive fraction (TPF) and false-positive fraction (FPF, 1   speciﬁcity) (B) for model with
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Examination Survey, 1999–2004. The horizontal dashed line in A indicates the prevalence of undiagnosed diabetes in the population (2.9%).
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Given the fact that little cost might be involved in collecting
information on family history of diabetes, the evaluation of
added value of using family history should mainly focus on
the magnitude of the beneﬁt rather than on cost-
effectiveness.
The limitations to our study include, ﬁrst, that NHANES
is a cross-sectional survey, and it cannot be used to predict
the risk of developing diabetes. Accordingly,we focused our
analysis on the improvements in detecting undiagnosed di-
abetes that might be realized by incorporating family history
of diabetes in a model. Second, NHANES 1999–2004 mea-
sured fasting glucose but did not assess glucose tolerance,
and thus it might have underestimated the prevalence of
diabetes. However, the American Diabetes Association has
recommended that, for epidemiologic studies and estimates
of diabetes prevalence, a fasting plasma glucose level of
 126 mg/dL (7.0 mmol/L) should be used (49). Third, di-
abetes was self-reported in NHANES 1999–2004, and re-
porting bias by different groups might exist. Studies
indicated that the proportion of undiagnosed diabetes was
higher in men, Mexican Americans, and the uninsured com-
pared with women, non-Hispanic whites, and the insured,
suggesting some reporting bias of diagnosed diabetes (50).
The prevalence of undiagnosed diabetes might be overrep-
resented in certain groups in NHANES 1999–2004. Fourth,
the family risk of diabetes was signiﬁcantly related to sex
and race/ethnicity (31, 51, 52). Women tend to have a better
knowledge of the presence of the disease among their rela-
tives, and the large families, for example, non-Hispanic
blacks and Mexican Americans compared with non-
Hispanic whites, are likely to have a greater possibility of
relatives with diabetes than the smaller families, especially
among populations where the disease prevalence is high. To
examine the possible effect of sex, ethnicity, or racial dif-
ferences in the familial risk of diabetes on the detection of
undiagnosed diabetes, we conducted stratiﬁed analysis by
sex and race/ethnicity; the results suggested that the im-
provements in detecting undiagnoseddiabetes by usingfam-
ily history of diabetes are consistent across sex and race/
ethnicity strata (Appendix Table 3). Fifth, there are no gen-
erally recognized risk thresholds for undiagnosed diabetes;
we arbitrarily used the quintile cutpoints of predicted risk
that included 20%, 40% 60%, or 80% of undiagnosed di-
abetes cases based on risk model 1. Some statistical mea-
sures of how well a model performs in prediction, such as
net reclassiﬁcation improvement, might be sensitive to the
risk thresholds used (23). Sixth, using the same data to ﬁt
a risk model and to assess its performance could lead to
overﬁtting. We conducted 5-fold cross-validation and ob-
tained an average weighted area under curve ¼ 0.84 for
the ﬁnal model with family history, and external validation
using the NHANES III (1988–1994) data set obtained
a weighted area under curve ¼ 0.89, indicating adequate
performance of our risk models.
The major strengths of our study include the availability
offasting glucose measurements from a nationally represen-
tative sample of the US adult population and the large num-
ber of potential risk factors for undiagnosed diabetes to
investigate.
Our ﬁndings suggest that family history of diabetes pro-
vides signiﬁcant improvements in the detection of additional
cases of undiagnosed diabetes, especially among people
with higher predicted risk. It also provides greater net ben-
eﬁts than a risk model without family history when applied
to the US population. Unlike other biomarkers, for example,
prostate-speciﬁc antigen for prostate cancer or C-reactive
protein for cardiovascular diseases, or genetic testing, ob-
taining information on family history of diabetes costs little,
and no adverse effect is associated with the process. With
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Figure 2. Weighted decision curves for models predicting undiagnosed diabetes using models with family history of diabetes (solid line) and
without this history(small dashedline), NationalHealth and NutritionExaminationSurvey, 1999–2004.The dash-dot-dot-dash line indicatesthenet
beneﬁt of testing all people, and the horizontal dashed line indicates testing none of the people. The y axis indicates the number of true cases
identiﬁed per 100 people.
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Am J Epidemiol 2010;171:1079–1089increased awareness and education, family history could be
a useful part of a public health tool designed for the de-
tection and control of diabetes in populations.
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Am J Epidemiol 2010;171:1079–1089Appendix Table 2. Weighted Net Beneﬁt and Differences in Net Beneﬁt for Testing All People for Undiagnosed Diabetes or According to Risk
Models With or Without Family History Using Selected Thresholds of Predicted Probabilities of Undiagnosed Diabetes, National Health and
Nutrition Examination Survey, 1999–2004
Predicted
Probability
of Events, %
True-Positive
Fraction, % 95% CI Models Net Beneﬁt, % 95% CI
a
Differences Between
Testing All vs. Model 1
and Model 1 vs. Model 2
95% CI
a
12.0 20.0 13.8, 29.6 Testing all
b  10.30  10.86, 9.85
Model 1
c 0.16  0.09, 0.39 10.5 9.99, 11.00
Model 2
d 0.32 0.03, 0.58 0.16 0.03, 0.33
7.3 40.0 29.4, 51.5 Testing all
b  4.70  5.23, 4.27
Model 1
c 0.44 0.10, 0.74 5.14 4.61, 5.65
Model 2
d 0.76 0.37, 1.13 0.32 0.06, 0.58
5.4 60.0 50.8, 69.5 Testing all
b  2.61  3.13, 2.19
Model 1
c 0.91 0.52, 1.21 3.52 3.11, 3.90
Model 2
d 0.96 0.55, 1.33 0.05  0.12, 0.32
3.6 80.0 71.5, 86.8 Testing all
b  0.69  1.2, 0.28
Model 1
c 1.41 1.00, 1.74 2.10 1.82, 2.37
Model 2
d 1.36 0.92, 1.68  0.03  0.23, 0.14
Abbreviation: CI, conﬁdence interval.
a Ninety-ﬁve percent conﬁdence intervals of the difference in net beneﬁt between testing all versus model 1 and model 1 versus model 2 were
estimated by using 1,000 rescaled bootstrap samples for complex surveys.
b Assuming that all people were tested for fasting glucose concentrations for diagnosis of diabetes.
c Model 1 included age, gender, body mass index, hypertension, and a high density lipoprotein cholesterol level of  35 mg/dL (0.90 mmol/L)
and/or a triglyceride level of  250 mg/dL.
d Model 2 included, in addition to the risk factors of model 1, family history of diabetes.
(Appendix continues on next page)
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Without Family History of Diabetes for Detecting Undiagnosed Diabetes Stratiﬁed by Sex and Race/Ethnicity, National Health and Nutrition
Examination Survey, 1999–2004
Statistical Measures
Models
Differences
(Model 1 2 Model 2) 95% CI
a
Without Family
History (Model 1)
b
With Family
History (Model 2)
c
Male
AIC
d 357.4 356.3 1.1  3.6, 9.9
Goodness-of-ﬁt test
e 7.4 (0.289) 3.5 (0.743)
Weighted C statistics 0.837 0.848 0.011 0.001, 0.024
R
2/IDI 0.0677 0.0734 0.006  0.001, 0.031
f
Female
AIC
d 247.3 239.2 8.1  0.5, 18.9
Goodness-of-ﬁt test
e 5.1 (0.280) 2.0 (0.732)
Weighted C statistics 0.820 0.847 0.027 0.005, 0.054
R
2/IDI 0.049 0.073 0.024 0.006, 0.065
f
Non-Hispanic white
AIC
d 319.6 316.4 3.2  2.6, 11.4
Goodness-of-ﬁt test
e 4.2 (0.124) 3.1 (0.213)
Weighted C statistics 0.848 0.863 0.015 0.003, 0.031
R
2/IDI 0.063 0.073 0.010 0.001, 0.039
f
Non-Hispanic black
AIC
d 131.9 128.3 3.6  3.2, 15.5
Goodness-of-ﬁt test
e 3.2 (0.788) 6.3 (0.392)
Weighted C statistics 0.831 0.856 0.025  0.006, 0.061
R
2/IDI 0.072 0.113 0.041 0.010, 0.125
f
Mexican American
AIC
d 125.7 118.5 7.3  3.3, 22.2
Goodness-of-ﬁt test
e 3.1 (0.381) 4.6 (0.203)
Weighted C statistics 0.854 0.896 0.042  0.003, 0.085
R
2/IDI 0.064 0.125 0.061 0.010, 0.191
f
Abbreviations: AIC, Akaike Information Criterion; CI, conﬁdence interval; IDI, integrated discrimination improvement.
a The 2.5 and 97.5 percentile distributions of 1,000 rescaled bootstrap samples of the differences between the different risk models.
b Model 1 was adjusted for age, gender, body mass index, hypertension, and a high density lipoprotein cholesterol level of  35 mg/dL (0.90
mmol/L) and/or a triglyceride level of  250 mg/dL.
c Model 2 included, in addition to the risk factors in model 1, family history of diabetes.
d The means and differences of AIC were generated from 1,000 rescaled bootstrap samples for the different risk models.
e Hosmer-Lemeshow goodness-of-ﬁt test; the numbers are v
2, with P values in parentheses.
f The difference between the R
2 of the 2 risk models equals the IDI.
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